-
IMO-2125 for Hepatitis C
Studying the safety of IMO-2125 in hepatitis C patients who are unresponsive to standard treatment with pegylated interferon and ribavirin.
Updated:
Mar. 24, 2009
About This Page
URL: http://www.dukehealth.org/Search?search_category=clinical_trials&search_string=gastroenterology